Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw some unusual options trading on Thursday. Stock traders acquired 4,052 call options on the company. This is an increase of 103% compared to the typical daily volume of 1,999 call options.
Reviva Pharmaceuticals Price Performance
Shares of NASDAQ:RVPH traded up $0.20 during midday trading on Thursday, reaching $2.01. The company's stock had a trading volume of 3,178,867 shares, compared to its average volume of 796,415. The business's fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.26. The company has a market capitalization of $67.22 million, a P/E ratio of -1.81 and a beta of -0.02. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $5.67.
Wall Street Analysts Forecast Growth
Separately, EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a "strong-buy" rating in a research report on Monday, September 23rd.
Read Our Latest Research Report on RVPH
Institutional Investors Weigh In On Reviva Pharmaceuticals
An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC boosted its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) by 17.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,496 shares of the company's stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 63.18% of the company's stock.
About Reviva Pharmaceuticals
(
Get Free Report)
Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
See Also
Before you consider Reviva Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reviva Pharmaceuticals wasn't on the list.
While Reviva Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
